Compare COCO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | MLYS |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2021 | 2023 |
| Metric | COCO | MLYS |
|---|---|---|
| Price | $53.77 | $24.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $58.13 | $48.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 04-29-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.60 | ★ 37.43 |
| EPS | ★ 1.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.12 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | $46.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.79 | $10.44 |
| 52 Week High | $61.39 | $47.65 |
| Indicator | COCO | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 39.48 |
| Support Level | $50.40 | $13.42 |
| Resistance Level | $55.43 | $31.09 |
| Average True Range (ATR) | 2.49 | 1.62 |
| MACD | -0.31 | -0.15 |
| Stochastic Oscillator | 32.98 | 24.24 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.